Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Centrus Energy Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Centrus Energy Corp trades at $189.56 (market cap $3.78B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.5× Centrus Energy Corp's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| BIO | LEU | |
|---|---|---|
Market Cap | $9.39B | $3.78B |
Sector | Health | Energy |
52-Week High | $356.25 | $436.00 |
52-Week Low | $241.71 | $146.61 |
Enterprise Value | $9.14B | $3.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Centrus Energy (LEU) trades at $191.37, up 7.49% in 24 hours, showing strong momentum amid bullish technical signals. Recent Q2 2026 earnings beat expectations with EPS of $0.77 versus $0.732 expected, though revenue growth is tempered by margin compression. The company secured a $900 million DOE contract and expanded its backlog to $4.5 billion, positioning it for long-term nuclear fuel demand. Analysts maintain a consensus buy rating with a $228.50 price target, reflecting optimism in its HALEU market dominance.
Outlook is positive due to government support and backlog visibility, but risks include high valuation (P/E 68.23), volatile cash flows, and execution challenges in scaling production. Investors should weigh growth potential against cost pressures and competitive dynamics in the nuclear sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
